These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29940824)

  • 1. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
    Latimer NR; White IR; Abrams KR; Siebert U
    Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
    Latimer NR; Abrams KR; Siebert U
    BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.
    Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
    Stat Methods Med Res; 2017 Apr; 26(2):724-751. PubMed ID: 25416688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.
    Latimer NR; White IR; Tilling K; Siebert U
    Stat Methods Med Res; 2020 Oct; 29(10):2900-2918. PubMed ID: 32223524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.
    Latimer NR; Abrams KR; Lambert PC; Morden JP; Crowther MJ
    Stat Methods Med Res; 2018 Mar; 27(3):765-784. PubMed ID: 27114326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.
    Latimer NR; Dewdney A; Campioni M
    BMC Med Res Methodol; 2024 Jan; 24(1):17. PubMed ID: 38253996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Validation Study of the Rank-Preserving Structural Failure Time Model: Confidence Intervals and Unique, Multiple, and Erroneous Solutions.
    Ouwens M; Hauch O; Franzén S
    Med Decis Making; 2018 May; 38(4):509-519. PubMed ID: 29607730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.
    Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
    Med Decis Making; 2014 Apr; 34(3):387-402. PubMed ID: 24449433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
    Fukuda M; Sakamaki K; Oba K
    Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjusting overall survival for treatment switches: commonly used methods and practical application.
    Watkins C; Huang X; Latimer N; Tang Y; Wright EJ
    Pharm Stat; 2013; 12(6):348-57. PubMed ID: 24136868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How serious is bias in effect estimation in randomised trials with survival data given risk heterogeneity and informative censoring?
    McNamee R
    Stat Med; 2017 Sep; 36(21):3315-3333. PubMed ID: 28621000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of censoring assumptions to reduce bias in tuberculosis treatment cohort analyses.
    Brooks MB; Mitnick CD; Manjourides J
    PLoS One; 2020; 15(10):e0240297. PubMed ID: 33075072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting.
    Sullivan TR; Latimer NR; Gray J; Sorich MJ; Salter AB; Karnon J
    Value Health; 2020 Mar; 23(3):388-396. PubMed ID: 32197735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restricted Net Treatment Benefit in oncology.
    Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
    J Clin Epidemiol; 2024 Jun; 170():111340. PubMed ID: 38570079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonignorable censoring in randomized clinical trials.
    Zhang J; Heitjan DF
    Clin Trials; 2005; 2(6):488-96. PubMed ID: 16422309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Evans R; Hawkins N; Dequen-O'Byrne P; McCrea C; Muston D; Gresty C; Ghate SR; Fan L; Hettle R; Abrams KR; de Bono J; Hussain M; Agarwal N
    Target Oncol; 2021 Sep; 16(5):613-623. PubMed ID: 34478046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correcting treatment effect for treatment switching in randomized oncology trials with a modified iterative parametric estimation method.
    Zhang J; Chen C
    Stat Med; 2016 Sep; 35(21):3690-703. PubMed ID: 26919271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials.
    Speiser JL; Ambrosius WT; Pajewski NM
    Clin Trials; 2023 Oct; 20(5):507-516. PubMed ID: 37243355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling.
    Kuehne F; Rochau U; Paracha N; Yeh JM; Sabate E; Siebert U
    Med Decis Making; 2022 Feb; 42(2):194-207. PubMed ID: 34666553
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.